Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

• Status: Recruiting
• Trial end date: 2026-03-01

Summary

The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with additional chemotherapy

• Phase: Phase 3

Details

• Lead Sponsor: Joel Neal; Stanford University
• Collaborator: AstraZeneca
• Treatments: Antibodies, Monoclonal; Carboplatin; Cisplatin; Durvalumab; Paclitaxel; Pemetrexed